Lundbeck Continues Strong Growth in Third Quarter
[Source: Lundbeck ]
ADD STORY TO CART
03-Nov-2010
Danish-based H. Lundbeck A/S, a pharmaceutical company specialized in central nervous system (CNS) disorders, reports third quarter revenue of DKK 3,619 million, an increase of 7% compared to the third quarter results of 2009. Profit from operations (EBIT) was DKK 846 million, an increase of 8% compared to the same period last year. The EBIT margin for the quarter was 23.4%. Continued strong growth in key products Cipralex®, Ebixa® and Azilect®, growing 11%, 9% and 28%...
Related Links & Documents
Lundbeck
Press Release